PT2977 是一种口服有效的，选择性 HIF-2α 抑制剂，IC50 为 9 nM。PT2977 作为第二代 HIF-2α 抑制剂，可提高效力并改善药代动力学特征。PT2977 是一种潜在的治疗透明细胞肾细胞癌 (ccRCC) 和 VHL 疾病的方法。
CAS：1672668-24-4
分子式：C17H12F3NO4S
分子量：383.34
纯度：98%
存储：Store at -20°C

Background:

PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for Clear cell renal cell carcinoma (ccRCC) and von Hippel-Lindau (VHL) disease[1]. IC50: 9 nM (HIF-2α)[1]

PT2977 potently and dose-dependently reduces mRNA levels of human cyclin D1, a target gene regulated by HIF-2α, and leads to rapid and dose-dependent reduction in EPO expression[1].

[1]. Xu R, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019 Aug 8;62(15):6876-6893.